CANCER CLUES
New study reveals weak spots in chemotherapy-resistant cancer cells
Molecular ‘weak spots' in cancer cells recovering from chemotherapy could provide the basis for better treatments, according to new research
Stories tagged with 'Drug discovery'
Breakout discovery
Cancer drugs could be delivered in molecular cages unlocked by light
Molecular cages created by Imperial researchers could lead to more targeted cancer drug delivery, causing greater efficiency and fewer side effects.
Anti-cancer drug centre
ADC Therapeutics to develop anti-cancer drugs in new White City Campus centre
Biotechnology company ADC Therapeutics is to launch a new research centre in Imperial’s White City Campus to develop next-generation cancer drugs.
Video
A better tomorrow
Imperial staff reflect on a challenging year – and their hopes for the future
In a new video, Imperial staff at the heart of the COVID-19 response share their thoughts on the challenges of 2020 – and hopes for the future.
CANCER TRIAL
Imperial set to lead UK trial of innovative new cancer drug
The trial will assess a promising new drug developed by Imperial scientists, designed to treat multiple myeloma and diffuse large b-cell lymphoma.
2
Drug investment
Imperial startup wins £4.5m investment to develop new cancer drugs
An Imperial startup has won £4.5m investment to develop drugs that could offer a safer and more effective way to treat certain drug-resistant cancers.
3
Under the microscope
Molecular insights into key drug target could help to enhance cancer treatments
New research reveals how a key protein in cells could be tweaked to make cancer treatments more effective.
TRIPLE THREAT
New anti-cancer drug combo treatment shows promise for myeloma patients
Phase 3 trial results reveal that selinexor – a relatively new anti-cancer drug – improves patient outcomes when combined with established treatments.
HTLV-1 INSIGHTS
Cancer-causing HTLV-1 virus hijacks cellular machinery to establish infection
Scientists have used a cutting-edge visualisation technique to show how the human T-cell lymphotropic virus, type 1 (HTLV-1) infects immune cells.
Chemical analysis suite
Agilent Measurement Suite celebrates early successes
Advanced chemical analysis equipment from Agilent in the Molecular Sciences Research Hub has been helping researchers solve pressing challenges.
